artificial intelligence Archives

Dr. Babyl: Artificial Intelligence Could Save Lives, Time and Money — TheDailyBeast.com

May 27th, 2019|Categories: HB Risk Notes|Tags: ai, AI Medicine, artificial intelligence, babyl, clinical trial, clinical trials, Doctor, future health care, global health, health care, international health, Medicine, UK|

Itchy throat? Headache? Upset stomach? There's an app for that. There is a new AI healthcare system called Babylon UK’s National Health Service which features an AI-driven app that is reportedly able to separate “run-of-the-mill” illnesses from more life-threatening ones, while saving time, money, and anxiety for patients and doctors alike. Babylon offers more than diagnostic assistance; it is accessible to people in remote areas. "For example, Babyl, the Rwandan version of Babylon, offers remote appointments with clinicians, fills prescriptions, orders lab tests, and issues referrals.” Babyl enables affordable, personalized healthcare, combined with “the brains of thousands of doctors at once” to reach patients who cannot get to a doctor’s officer. In addition to assisting doctors with everyday check-ups and treating the common cold, the AI’s abilities extend to clinical trials. “In 2018 the Mayo Clinic partnered with IBM’s Watson to match patients with breast cancer to accessible clinical trials covered by their health plans. The matching program increased the enrollment of breast cancer sufferers in Mayo Clinic’s own clinical trials by 80%." Questions are being raised, however, about how to mitigate risks posed by hacking or by nefarious manipulation of the system. Read about this and more in the complete post by Joelle Renstrom on TheDailyBeast.com.

Oracle Health Sciences on Pharmacovigilance and Artificial Intelligence

August 22nd, 2018|Categories: HB Risk Notes, HB Tort Notes|Tags: adverse incident, artificial intelligence, drug safety, pharma regulation, pharmacovigilance|

"The potential to use artificial intelligence methods increasingly for the analysis of the increasing amounts of pharmacovigilance data is well understood and many companies are moving (or planning to move) there, and we can predict that routine tasks in pharmacovigilance will in the future be increasingly automated. It will be crucial, however, for regulatory authorities to very clearly provide a position about the use of AI as well as the acceptable level of quality from AI applications. But in parallel with the shaping of those definitions, given the massive increase in their AE case workloads that most companies are currently experiencing, the industry will out of necessity proceed swiftly with the adoption of AI and cloud technologies to reduce their costs and increase their efficiencies. "Like other industries, the pharmaceutical business and in particular the pharmacovigilance field will see a massive change in their processes in the near future, away from tedious, repetitive manual tasks towards a better utilization of scarce resources, in particular medical and scientific knowledge, for value-adding tasks. It is imperative for all stakeholders – industry, service providers and regulators – to provide an environment in which such a transformation can take place without ever compromising public health or the safety of the individual patient, and ideally providing additional benefit for patients." A quote from Addressing the Data Challenges [...]

Artificial Intelligence in the Drug and Device Industries

August 9th, 2018|Categories: HB Tort Notes|Tags: artificial intelligence, drug discovery, drug law, drug tech, drugs and devices, pharma tech|

Are Data Divers and Miners Going to Lead Innovation? The big tech companies are into it. Apple, IBM and Google. Roche is into it. Medtronic, as well. Artificial intelligence has been a big part of innovation in the healthcare space for several years, and its impact is only going to get bigger. "Artificial intelligence-based healthcare technologies have contributed to improved drug discoveries, tumor identification, diagnosis, risk assessments, electronic health records (EHR), and mental health tools, among others," writes Blank Rome attorney Brian Higgins in his Artificial Intelligence and the Law Blog (it's excellent, by the way). [1] Daniel Faggella of TechEmergence.com writes that machine learning healthcare applications are getting a lot of attention in the press and from the investment community. He adds to the list of machine learning's impact things like treatment queries and suggestions, and even robotic surgery. But optimism for AI's application to drug discovery seems greater than that inspired by other healthcare sectors. One reason for that, Faggella writes, is that compared to other segments where various laws and stakeholder incentives may not align, "drug discovery stands out as a relatively straightforward economic value for machine learning healthcare application creators." He adds that this application also involves "one relatively clear customer who happens to generally have deep pockets: drug companies." [2] Also writing for TechEmergence.com, Kumba Sennaa says [...]

McLoughlin on Artificial Intelligence in Banking

July 25th, 2018|Categories: HB Risk Notes|Tags: artificial intelligence|

"Capital adequacy requirements are not the only kind of regulation that AI is helping banks to meet. An even bigger area is monitoring of trading activities for misconduct and abuse. The Bank of England estimates that misconduct by traders has cost banks a global cumulative of $320 billion to date. For this very large reason, banks are aggressively deploying machine learning to monitor the behavior of their traders and detect unusual behavior." Read Michael McLoughlin's post on LinkedIn. Michael McLoughlin is Global Digital Transformation Partner & Advocate with Microsoft.

Brian Higgins’ A.I. Law Blog: Will Facebook Facial Recognition Case be a Referendum on A.I.?

June 5th, 2018|Categories: HB Risk Notes|Tags: artificial intelligence, biometric information, facial recognition|

When most of us upload our selfies and photo bombs to the web, and some do it more than is healthy and way more than is desired -- also, please stop -- we have no idea how much is going on. You might think it's just you photo-bombing a beer bottle, but what exactly happens after that depends on who you ask. One thing is for sure: it's more technical than most of us will grasp or ever want to. Another thing is for sure: the answer could mean millions or even billions of dollars. Is your goofball face being "scanned"? Are the pixels being examined or is some technological magic wand measuring the distance between your eyeballs? And what's being done with that information? Do you know? Do you care? In his blog, "engineer turned attorney" Brian Higgins dives into the questions as being posed in the Facebook facial recognition case pending before U.S. Judge James Donato in San Francisco. Higgins says that next month a jury will have to decide whether Facebook's A.I. technology creates "biometric information" which is regulated under the Illinois Biometric Information Privacy Act, or BIPA. "In some respects," Higgins writes, "the jury’s decision could reflect general sentiment toward AI during a time when vocal opponents of AI have been widely covered in the media. The outcome could also [...]

Northeast Corporate Counsel Forum | April 24, 2018 | New York

January 9th, 2018|Categories: HB Risk Notes|Tags: artificial intelligence, autonomous vehicles, complex litigation, cyber forensics, digital forensics, legal costs, litigation budgets, lobbying law, phishing, Product Liability, social engineering|

Conference Chairs CHARITY C. HYDE Member Bennett, Bricklin & Saltzburg, LLC JACOB S. PARSONS Managing Director The Claro Group Where The Roosevelt Hotel 45 East 45th Street New York, NY 888-833-3969 CLE This event will be eligible for CLE Conference Registration Rates Complimentary: In-house counsel (space limited) *2 per/co. $450 each add'l $695: Attorneys in private practice $395: Attendees from speaker firms; paralegals; legal admins $450: Insurance claims administrators $1,195: Litigation service providers Complimentary: Sitting judges Register or Sponsor via Our Sales Team: Suzanne Armstrong Office: 484.324-2755 x2050 Brownie Bokelman Office: 484.324-2755 x2120 Contact Us (484) 324-2755 Send us an Email Speaking Proposals Send us your idea Sponsors Contact Suzanne for our 2018 Sponsor Menu! Ask her about the new HB Target Sponsorship Get the people there you want! Suzanne Armstrong Sales Representative Email (484) 324-2755 x2050 Want to speak at a future event? Send us your idea! Look who's attending! Akzo Nobel Inc. | Allianz Global Corporate & Specialty Allied World Insurance Company | Allstate Insurance Company | Altria Client Services LLC | American Airlines| Ameriprise Financial | Ankura Consulting Group LLC | AXA Liabilities Managers, Inc. | BAI | Bayer | BDP International | Bennett, Bricklin & Saltzburg LLC | Berkley Cyber Risk Solutions | BMWNA, LLC | BMW [...]